 |
| B cells are involved in a number of immune functions, including antibody generation. Given their importance in B cell lymphomas and some autoimmune diseases, the depletion of B cells with monoclonal antibodies is an essential FDA approved treatment, as well as a very active field of research. In particular, CD20, which aids in calcium influx, activation and proliferation of B cells, can be found on pre-B cells and the stages of differentiation that follow (with the exception of plasma cells). BioLegend is proud to announce the release of a new clone, SA271G2, which exhibits the ability to deplete murine B cells in vivo, providing a valuable research tool for investigators. |
In vivo depletion protocol
|
| C57BL/6 mice were injected i.v. with 250 µg of Ultra-LEAF™ purified mAb SA271G2 or Ultra-LEAF™ purified rat IgG2b, κ isotype control. To study the presence of B cells in different compartments, the mice were either bled or euthanized with CO2 at day 7, and spleen, lymph nodes, bone marrow, and the peritoneal cavity lavage were collected and stained with the indicated antibodies. |
Spleen sections demonstrate loss of B cells with administration of clone SA271G2
|
 |
| C57BL/6 mice were injected i.v. with 250 µg of purified rat IgG2b, κ isotype control (left) or Ultra-LEAF™ purified anti-mouse CD20 (clone SA271G2) (right). At day 7, Immunofluorescence staining of spleen frozen sections shows depletion of the different B cell subsets in mice that were injected with clone SA271G2. T cells, macrophage subsets, and overall architecture of the spleen are not affected by SA271G2 treatment. |
B cells are depleted from mouse blood using clone SA271G2
|
Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
Follow Us